Eli Chan

4.8k total citations
76 papers, 3.8k citations indexed

About

Eli Chan is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, Eli Chan has authored 76 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 27 papers in Pharmacology and 26 papers in Oncology. Recurrent topics in Eli Chan's work include Pharmacogenetics and Drug Metabolism (21 papers), Drug Transport and Resistance Mechanisms (15 papers) and Pharmacological Effects and Toxicity Studies (11 papers). Eli Chan is often cited by papers focused on Pharmacogenetics and Drug Metabolism (21 papers), Drug Transport and Resistance Mechanisms (15 papers) and Pharmacological Effects and Toxicity Studies (11 papers). Eli Chan collaborates with scholars based in Singapore, China and New Zealand. Eli Chan's co-authors include Shu‐Feng Zhou, Wei Duan, Min Huang, Sui Yung Chan, Shufeng Zhou, Zeping Hu, Hwee‐Ling Koh, Yihuai Gao, Boon Cher Goh and Xiaotian Li and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, Pharmaceutical Research and Clinical Pharmacology & Therapeutics.

In The Last Decade

Eli Chan

76 papers receiving 3.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eli Chan Singapore 32 1.5k 1.2k 840 826 609 76 3.8k
Dafang Zhong China 36 1.1k 0.8× 1.8k 1.5× 913 1.1× 1.2k 1.4× 337 0.6× 266 5.2k
Hong‐Hao Zhou China 38 1.4k 1.0× 1.3k 1.1× 1.3k 1.5× 567 0.7× 295 0.5× 165 4.7k
Reginald F. Frye United States 40 1.8k 1.2× 1.0k 0.8× 924 1.1× 924 1.1× 287 0.5× 160 5.2k
Bill J. Gurley United States 30 1.5k 1.0× 706 0.6× 460 0.5× 1.2k 1.4× 1.2k 1.9× 110 4.2k
Zhi‐Rong Tan China 31 1.2k 0.8× 774 0.7× 704 0.8× 412 0.5× 253 0.4× 103 2.8k
Michael T. Murray Australia 44 2.4k 1.6× 2.0k 1.7× 1.4k 1.7× 530 0.6× 250 0.4× 243 6.3k
Hye Suk Lee South Korea 39 935 0.6× 2.4k 2.0× 529 0.6× 676 0.8× 304 0.5× 254 5.1k
Qiang Meng China 39 974 0.7× 1.9k 1.6× 1.3k 1.5× 396 0.5× 285 0.5× 185 4.7k
Huichang Bi China 37 1.3k 0.9× 1.9k 1.6× 842 1.0× 319 0.4× 312 0.5× 178 4.2k
Kan He United States 41 1.3k 0.9× 1.9k 1.6× 748 0.9× 401 0.5× 424 0.7× 109 5.8k

Countries citing papers authored by Eli Chan

Since Specialization
Citations

This map shows the geographic impact of Eli Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eli Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eli Chan more than expected).

Fields of papers citing papers by Eli Chan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eli Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eli Chan. The network helps show where Eli Chan may publish in the future.

Co-authorship network of co-authors of Eli Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Eli Chan. A scholar is included among the top collaborators of Eli Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eli Chan. Eli Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sun, Feng, et al.. (2011). Development of stealth liposome coencapsulating doxorubicin and fluoxetine. Journal of Liposome Research. 21(4). 261–271. 21 indexed citations
2.
Sun, Feng, Eli Chan, Zhenlong Wu, et al.. (2009). Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. Molecular Cancer Therapeutics. 8(12). 3191–3202. 63 indexed citations
3.
4.
Yu, Xi-Yong, Lin Shu-guang, Xiaohong Chen, et al.. (2007). Transport of Cryptotanshinone, a Major Active Triterpenoid in Salvia Miltiorrhiza Bunge Widely Used in the Treatment of Stroke and Alzheimers Disease, Across the Blood-Brain Barrier. Current Drug Metabolism. 8(4). 365–377. 75 indexed citations
5.
Hu, Zeping, Xiao-Xia Yang, Xiao Chen, et al.. (2007). A Mechanistic Study on Altered Pharmacokinetics of Irinotecan by St. Johns Wort. Current Drug Metabolism. 8(2). 157–171. 22 indexed citations
6.
Wang, Xueding, Jiali Li, Xiǎoyīng Dèng, et al.. (2007). A Pharmacogenetic Study of Pregnane X Receptor (NR1I2) in Han Chinese. Current Drug Metabolism. 8(8). 778–786. 20 indexed citations
7.
Yang, Xiao-Xia, Zeping Hu, Wei Duan, et al.. (2006). A Mechanistic Study on Reduced Toxicity of Irinotecan by Coadministered Thalidomide, a Tumor Necrosis Factor-α Inhibitor. Journal of Pharmacology and Experimental Therapeutics. 319(1). 82–104. 27 indexed citations
8.
Zhong, Shilong, Shufeng Zhou, Xiaohong Chen, et al.. (2006). Relationship between genotype and enzyme activity of glutathione S-transferases M1 and P1 in Chinese. European Journal of Pharmaceutical Sciences. 28(1-2). 77–85. 65 indexed citations
9.
Yang, Xiao-Xia, et al.. (2006). Pharmacokinetics of Recombinant Human Endostatin in Rats. Current Drug Metabolism. 7(6). 565–576. 10 indexed citations
10.
Yang, Xiao-Xia, Zeping Hu, Sui Yung Chan, et al.. (2006). Pharmacokinetic Mechanisms for Reduced Toxicity of Irinotecan by Coadministered Thalidomide. Current Drug Metabolism. 7(4). 431–454. 10 indexed citations
11.
Tian, Quan, Jing Zhang, Sui Yung Chan, et al.. (2005). Topotecan Is a Substrate for Multidrug Resistance Associated Protein 4. Current Drug Metabolism. 7(1). 105–118. 56 indexed citations
12.
Gao, Yihuai, Wenbo Tang, Xihu Dai, et al.. (2005). Effects of Water-Soluble Ganoderma lucidum Polysaccharides on the Immune Functions of Patients with Advanced Lung Cancer. Journal of Medicinal Food. 8(2). 159–168. 64 indexed citations
13.
Tang, Wenbo, Yihuai Gao, Guoliang Chen, et al.. (2005). A Randomized, Double-Blind and Placebo-Controlled Study of a Ganoderma lucidum Polysaccharide Extract in Neurasthenia. Journal of Medicinal Food. 8(1). 53–58. 48 indexed citations
14.
Tian, Quan, Jing Zhang, Theresa May Chin Tan, et al.. (2005). Human Multidrug Resistance Associated Protein 4 Confers Resistance to Camptothecins. Pharmaceutical Research. 22(11). 1837–1853. 87 indexed citations
15.
Yang, Xiaoxia, Zeping Hu, Sui Yung Chan, et al.. (2005). Novel Agents that Potentially Inhibit Irinotecan-Induced Diarrhea. Current Medicinal Chemistry. 12(11). 1343–1358. 40 indexed citations
16.
Yang, Xiaoxia, Zeping Hu, Sui Yung Chan, et al.. (2005). Determination of thalidomide by high performance liquid chromatography: Plasma pharmacokinetic studies in the rat. Journal of Pharmaceutical and Biomedical Analysis. 39(1-2). 299–304. 15 indexed citations
17.
Li, Jing, Shu‐Feng Zhou, Hung Huynh, & Eli Chan. (2005). Significant Intestinal Excretion, One Source of Variability in Pharmacokinetics of COL-3, a Chemically Modified Tetracycline. Pharmaceutical Research. 22(3). 397–404. 8 indexed citations
18.
Zhou, Shu‐Feng, Sui Yung Chan, Boon Cher Goh, et al.. (2005). Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs. Clinical Pharmacokinetics. 44(3). 279–304. 391 indexed citations
19.
Gao, Yihuai, Wenbo Tang, He Gao, et al.. (2004). Ganoderma lucidum Polysaccharide Fractions Accelerate Healing of Acetic Acid-Induced Ulcers in Rats. Journal of Medicinal Food. 7(4). 417–421. 39 indexed citations
20.
Chan, Eli. (1993). Displacement of Bilirubin from Albumin by Berberine. Neonatology. 63(4). 201–208. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dafang Zhong Breakdown of academic impact, for papers by Hong‐Hao Zhou Breakdown of academic impact, for papers by Reginald F. Frye Breakdown of academic impact, for papers by Bill J. Gurley Breakdown of academic impact, for papers by Zhi‐Rong Tan Breakdown of academic impact, for papers by Michael T. Murray Breakdown of academic impact, for papers by Hye Suk Lee Breakdown of academic impact, for papers by Qiang Meng Breakdown of academic impact, for papers by Huichang Bi Breakdown of academic impact, for papers by Kan He
Rankless by CCL
2026